» Articles » PMID: 23521314

A Time-to-event Model for Acute Rejections in Paediatric Renal Transplant Recipients Treated with Ciclosporin A

Overview
Specialty Pharmacology
Date 2013 Mar 26
PMID 23521314
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Ciclosporin A (CsA) dosing in immunosuppression after paediatric kidney transplantation remains challenging, and appropriate target CsA exposures (AUCs) are controversial. This study aimed to develop a time-to-first-acute rejection (AR) model and to explore predictive factors for therapy outcome.

Methods: Patient records at the Children's Hospital in Helsinki, Finland, were analysed. A parametric survival model in NONMEM was used to describe the time to first AR. The influences of AUC and other covariates were explored using stepwise covariate modelling, bootstrap-stepwise covariate modelling and cross-validated stepwise covariate modelling. The clinical relevance of the effects was assessed with the time at which 90% of the patients were AR free (t90).

Results: Data from 87 patients (0.7-19.8 years old, 54 experiencing an AR) were analysed. The baseline hazard was described with a function changing in steps over time. No statistically significant covariate effects were identified, a finding substantiated by all methods used. Thus, within the observed AUC range (90% interval 1.13-8.40 h mg l⁻¹), a rise in AUC was not found to increase protection from AR. Dialysis time, sex and baseline weight were potential covariates, but the predicted clinical relevance of their effects was low. For the strongest covariate, dialysis time, median t90 was 5.8 days (90% confidence interval 5.1-6.8) for long dialysis times (90th percentile) and 7.4 days (6.4-11.7) for short dialysis times (10th percentile).

Conclusions: A survival model with discrete time-varying hazards described the data. Within the observed range, AUC was not identified as a covariate. This feedback on clinical practice may help to avoid unnecessarily high CsA dosing in children.

Citing Articles

Midazolam Infusion and Disease Severity Affect the Level of Sedation in Children: A Parametric Time-to-Event Analysis.

Upadhyay P, Vet N, Goulooze S, Krekels E, de Wildt S, Knibbe C Pharm Res. 2021; 38(10):1711-1720.

PMID: 34664207 PMC: 8523120. DOI: 10.1007/s11095-021-03113-w.


A Repeated Time-to-Positive Symptoms Improvement among Malaysian Patients with Schizophrenia Spectrum Disorders Treated with Clozapine.

Albitar O, Harun S, Ahmad S, Sheikh Ghadzi S Pharmaceutics. 2021; 13(8).

PMID: 34452082 PMC: 8401956. DOI: 10.3390/pharmaceutics13081121.


Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms.

DAgate S, Chavan C, Manyak M, Palacios-Moreno J, Oelke M, Michel M Br J Clin Pharmacol. 2020; 87(7):2777-2789.

PMID: 33247951 PMC: 8359386. DOI: 10.1111/bcp.14682.


Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy.

Lindauer A, Laveille C, Stockis A Clin Pharmacokinet. 2017; 56(11):1403-1413.

PMID: 28290119 PMC: 5648747. DOI: 10.1007/s40262-017-0530-8.


Pharmacodynamic Analysis of Morphine Time-to-Remedication Events in Infants and Young Children After Congenital Heart Surgery.

Elkomy M, Drover D, Galinkin J, Hammer G, Glotzbach K Clin Pharmacokinet. 2016; 55(10):1217-1226.

PMID: 27098060 DOI: 10.1007/s40262-016-0398-z.


References
1.
Qvist E, Their M, Krogerus L, Holmberg C, Jalanko H . Early treatment of acute rejections gives favorable long-term function after renal transplantation in small children. Pediatr Transplant. 2007; 11(8):895-900. DOI: 10.1111/j.1399-3046.2007.00761.x. View

2.
Jonsson E, Karlsson M . Automated covariate model building within NONMEM. Pharm Res. 1998; 15(9):1463-8. DOI: 10.1023/a:1011970125687. View

3.
Lindbom L, Pihlgren P, Jonsson E, Jonsson N . PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005; 79(3):241-57. DOI: 10.1016/j.cmpb.2005.04.005. View

4.
Browne B, Young J, Dunn T, Matas A . The impact of cytomegalovirus infection ≥1 year after primary renal transplantation. Clin Transplant. 2010; 24(4):572-7. PMC: 3553593. DOI: 10.1111/j.1399-0012.2010.01208.x. View

5.
Pollard S, Lear P, Ready A, Moore R, Johnson R . Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group. Transplantation. 1999; 68(9):1325-31. DOI: 10.1097/00007890-199911150-00018. View